ERBB2 and breast cancer: Joint analyses of the landmark NSABP B-31 and NCCTG N9831 clinical trials showed significantly improved disease-free survival (DFS) and overall survival (OS) with adjuvant chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) and trastuzumab in patients with HER2+ early breast cancer (1).